N※N

Supplement Industry Lobbies FDA for Regulatory Overhaul

  //food-wine.news-articles.net/content/2026/03/29 .. ndustry-lobbies-fda-for-regulatory-overhaul.html
  Published in Food and Wine on Sunday, March 29th 2026 at 11:54 GMT by ABC7 San Francisco
      Locale: UNITED STATES

SAN FRANCISCO, CA - March 29th, 2026 - The dietary supplement industry is intensifying its lobbying efforts with the Food and Drug Administration (FDA), advocating for a modernized regulatory framework that would permit the inclusion of innovative ingredients like peptides and other novel compounds currently excluded from the market. Industry leaders argue that the existing regulations, while intended to protect public health, are inadvertently stifling innovation and restricting consumer access to potentially beneficial products.

The current system, established decades ago, operates under the Dietary Supplement Health and Education Act (DSHEA) of 1994. This act places the onus on supplement manufacturers to ensure the safety of their products after they are on the market - a significant departure from the pre-market approval requirements imposed on pharmaceuticals and, increasingly, on certain functional foods. While the FDA can intervene if a supplement is demonstrably unsafe or mislabeled, the industry contends this reactive approach is inadequate for evaluating the potential of emerging ingredients.

"The landscape of nutritional science has changed dramatically since DSHEA was enacted," explains Chris Kerig, General Counsel for the Council for Responsible Nutrition (CRN), a leading industry trade association. "We're not advocating for deregulation, but for a clear, scientifically-grounded pathway to demonstrate the safety and efficacy of ingredients that don't fit neatly into traditional food or drug categories. Consumers deserve access to innovation, but that innovation must be backed by evidence."

The debate centers largely around ingredients like peptides - short chains of amino acids, the building blocks of proteins. Peptides are increasingly being researched for a wide range of potential health benefits, from muscle recovery and immune support to cognitive enhancement and anti-aging properties. However, due to their novel structure and the lack of a defined regulatory pathway, the FDA currently prohibits their use in dietary supplements. This effectively blocks companies from bringing peptide-based products to market, even those supported by preliminary scientific research.

The industry's proposed solution isn't a complete overhaul of the regulatory system, but rather the creation of a tiered notification process. This would allow companies to submit scientific data - including safety studies, manufacturing details, and proposed labeling - for review by the FDA. A risk-based assessment could then be applied, with ingredients posing minimal risk potentially receiving expedited approval, while those requiring further investigation undergoing more rigorous scrutiny.

The FDA, however, remains cautious. "Our primary responsibility is to ensure the safety of the food supply, and that includes dietary supplements," stated FDA spokesperson Alisa Roberts. "We're committed to working with industry stakeholders, but we won't compromise on our commitment to public health. Any new regulatory pathway must prioritize safety and prevent the introduction of harmful products into the market."

The agency's stance is partially informed by a history of concerns regarding the supplement industry. In recent years, the FDA has significantly increased its enforcement efforts, cracking down on companies making unsubstantiated health claims, adulterating products with illegal substances, and failing to adhere to Good Manufacturing Practices (GMPs). Instances of contamination, mislabeling, and deceptive marketing have fueled consumer skepticism and prompted calls for stricter oversight.

The push for regulatory reform also comes at a time when consumer interest in personalized nutrition and preventative healthcare is rapidly growing. Many consumers are actively seeking out supplements tailored to their specific needs and health goals. This demand is driving innovation within the industry, but also exacerbating the frustration over regulatory hurdles. Companies are often forced to operate in a legal gray area, or to develop products overseas where regulations may be less stringent.

Several analysts predict that a compromise between the industry and the FDA is likely. A modernized regulatory pathway could not only foster innovation but also enhance consumer confidence in the supplement market. However, the details of such a pathway - including the types of data required for approval, the level of FDA oversight, and the enforcement mechanisms - will be critical in ensuring the safety and integrity of the dietary supplement supply chain. The coming months are expected to see intense negotiations between industry representatives, FDA officials, and consumer advocacy groups as they work to shape the future of supplement regulation.